Story perspectives

AbbVie Poised for $230, Alibaba Faces Resistance

3/19/2025

26 6

Summary

AbbVie Investment Outlook

Elliott Wave analysis suggests AbbVie (ABBV) could reach $230, while CAT, CRM, CVX, and PANW are correcting.
Alibaba (BABA) encounters resistance at $168, signaling a possible end to its corrective rally.
Trading Lounge highlights investment risks and recommends consulting financial advisors prior to making trading decisions.

Summary

Market Trends Analysis

The Hang Seng Index shows a bullish trend, nearing completion of Orange Wave 1, with an invalidation level at 18,672.39.
ASX Limited shifts from a corrective wave to an Impulse Wave, targeting around $80.00, with an invalidation point at $62.03.
HCL Technology enters a counter-trend phase, with Navy Blue Wave A suggesting potential volatility; invalidation is at 2013.80.
GBP/AUD is in a corrective phase, with Orange Wave 2 anticipated before a new trend; invalidation level is 1.96381.
Mahindra & Mahindra remains bullish, with Navy Blue Wave 1 expected to rise before Navy Blue Wave 2; invalidation is at 2550.

History

Historical Context

Recent stock market trends echo historical patterns of volatility. Just as the 2008 financial crisis stemmed from overconfidence and risky investments, current fluctuations in companies like Alibaba signal investor caution amid regulatory scrutiny. Past events highlight how market sentiment can shift rapidly, impacting valuations significantly.

1 of 3

AbbVie Investment Outlook

Elliott Wave analysis suggests AbbVie (ABBV) could reach $230, while CAT, CRM, CVX, and PANW are correcting.
Alibaba (BABA) encounters resistance at $168, signaling a possible end to its corrective rally.
Trading Lounge highlights investment risks and recommends consulting financial advisors prior to making trading decisions.

1 / 3